STOCK TITAN

Bioventus Inc. - BVS STOCK NEWS

Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.

Bioventus Inc. (Nasdaq: BVS) is a global leader in orthobiologics, committed to providing innovative solutions that enhance the body’s natural healing processes. The company offers a comprehensive array of medical technology products designed to support musculoskeletal healing, including orthobiologic treatments, surgical solutions, and pain management therapies.

Founded in 2012 and headquartered in Durham, North Carolina, Bioventus has grown to employ nearly 600 professionals worldwide, with international offices in Hoofddorp, the Netherlands; Memphis, Tennessee; Australia; Canada; and a research and development site in Boston. The company’s mission is to help patients resume and enjoy active lives by delivering clinically proven, cost-effective products that ensure quick and safe recovery.

Bioventus operates through two main product portfolios: Bioventus Active Healing Therapies and Bioventus Surgical. These portfolios are enhanced through internal product development, strategic acquisitions, and distribution agreements. Their diverse range of products spans various medical specialties, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery.

Financially, Bioventus has demonstrated resilience and growth, reporting in its latest quarterly results a robust increase in adjusted EBITDA and significant improvements in cash flow and operating income. Despite a slight dip in total net sales, the company saw strong volumes in Surgical Solutions and substantial growth in its international markets.

Recent highlights include management’s focused efforts to stabilize operations, enhance liquidity, and maintain spending discipline. This strategic approach has positioned Bioventus to accelerate revenue growth and create long-term value for its stakeholders. The company continues to be a trusted partner to physicians and healthcare providers globally, offering high-quality, evidence-based medical solutions.

Rhea-AI Summary
Bioventus CEO to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
conferences
-
Rhea-AI Summary
Bioventus Inc. reports Q2 net sales of $137.1 million, down 2.3% YoY. Adjusted EBITDA increases 26.1% to $28.2 million. Loss per share of Class A common stock decreases to $0.06. Non-GAAP earnings per share of Class A common stock increase to $0.14. Total net sales decline due to lower Pain Treatment pricing and Wound Business divestiture. Gross margin decreases to 65.0%. Operating income improves to $6.8 million. Net loss from continuing operations decreases to $4.7 million. Adjusted EBITDA increases to $28.2 million. Non-GAAP net income and earnings per share of Class A common stock increase to $10.9 million and $0.14, respectively. Company expects net sales of $490 million to $505 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.27%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.17%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.48%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
conferences earnings

FAQ

What is the current stock price of Bioventus (BVS)?

The current stock price of Bioventus (BVS) is $9.97 as of January 23, 2025.

What is the market cap of Bioventus (BVS)?

The market cap of Bioventus (BVS) is approximately 657.6M.

What does Bioventus Inc. specialize in?

Bioventus Inc. specializes in orthobiologics, providing products for musculoskeletal healing, regeneration, and biosurgery that enhance the body's natural healing processes.

Where is Bioventus Inc. headquartered?

Bioventus Inc. is headquartered in Durham, North Carolina, with international offices in Hoofddorp, the Netherlands, and other locations worldwide.

What are the main product portfolios of Bioventus?

Bioventus operates through two main product portfolios: Bioventus Active Healing Therapies and Bioventus Surgical.

How does Bioventus improve its product offerings?

Bioventus enhances its product offerings through internal product development, strategic acquisitions, and distribution agreements.

What medical specialties does Bioventus cater to?

Bioventus caters to various medical specialties, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery.

What recent financial achievements has Bioventus made?

Bioventus recently reported significant growth in adjusted EBITDA, improved cash flow, and operating income, despite a slight decline in total net sales.

What is the mission of Bioventus?

The mission of Bioventus is to help patients resume and enjoy active lives by providing clinically proven, cost-effective products that ensure quick and safe recovery.

How does Bioventus contribute to patient care?

Bioventus contributes to patient care by offering innovative orthobiologic products that support musculoskeletal healing and enhance the body’s natural healing processes.

What are Bioventus’s strategic priorities?

Bioventus’s strategic priorities include stabilizing operations, enhancing liquidity, maintaining spending discipline, and accelerating revenue growth to create long-term value.

How is Bioventus positioned in the global market?

Bioventus is a trusted partner for physicians and healthcare providers worldwide, known for its high-quality, evidence-based medical solutions and commitment to ethical behavior.
Bioventus Inc.

Nasdaq:BVS

BVS Rankings

BVS Stock Data

657.60M
57.73M
11.56%
69.85%
1.49%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
DURHAM